Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

An Efficacy and Safety Study of JNJ-42756493 in Participants with Urothelial Cancer Ended

2023-510273-34-00 Urothelial cancer 4 2015-04-24
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Ended

2023-508606-26-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2015-04-23
An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl… Ended

2023-505102-42-00 Solid Malignant Tumors 5 2014-12-18
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended

2024-516137-13-00 Metastatic Prostate Cancer 5 2014-12-18
PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended

2024-519019-32-00 Early breast cancer 4 2014-12-05
PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended

2023-508411-23-00 Primary breast cancer 4 2014-11-12
Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit… Ended

2024-512243-23-00 gastrointestinal stromal tumor 5 2014-11-07
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Ended

2023-506779-82-00 Non Small Cell Lung Cancer 5 2014-11-04
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Ended

2024-514904-14-00 Patients with metastatic or unresectable locally advanc 4 2014-10-08
A Study of abemaciclib Combined with Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Ended

2023-506781-30-00 Breast cancer 5 2014-09-17
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended

2024-513455-33-00 Bone sarcoma 4 2014-09-11
Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) – a randomized controlled trial Ended

2023-510039-12-00 Non-functioning pituitary adenoma 6 2014-09-01
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502324-48-00 Patients with resected colon carcinoma 5 2014-08-05
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer Ended

2023-509511-84-00 Advanced HR+ breast cancer 9 2014-03-19
A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res… Ended

2023-509221-47-00 Castration-Resistant Prostate Cancer 5 2014-02-12
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended

2023-503803-27-00 B-cell non-Hodgkin's lymphoma and cGVHD 5 2013-10-25
Neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer (NeoCol) Ended

2024-514294-22-01 Colon cancer 5 2013-10-14
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin… Ended

2024-516202-39-00 Metastatic breast cancer 4 2013-10-10
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Ended

2024-511142-39-00 BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cance 5 2013-09-06
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended

2024-515368-29-00 patients with node positive breast cancer who do not ha 5 2012-09-20
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N… Ended

2024-516801-22-00 Patients with 1-3 positive Nodes, Hormone Receptor-Posi 5 2012-04-26